Search

Search Constraints

You searched for: Author/Creator Maru, Benit

Search Results

1. 253  Economic burden of care and treatment options for Rett syndrome: two systematic literature reviews. Issue 6 (27th May 2022)

2. An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). Issue 1 (1st January 2021)

3. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. Issue 1 (1st January 2019)

4. Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapy. Issue 2 (12th December 2018)